• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Day One Biopharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Completion of Acquisition or Disposition of Assets, Leadership Update

    4/23/26 8:54:03 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DAWN alert in real time by email
    8-K
    --12-31 false 0001845337 0001845337 2026-04-22 2026-04-22
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): April 22, 2026

     

     

    DAY ONE BIOPHARMACEUTICALS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-40431   83-2415215

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    1800 Sierra Point Parkway, Suite 200

    Brisbane, California

      94005
    (Address of principal executive offices)   (Zip Code)

    Registrant’s telephone number, including area code: (650) 484-0899

    N/A

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, par value $0.0001 per share   DAWN   Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    INTRODUCTORY NOTE

    As previously reported in the Current Report on Form 8-K filed on March 6, 2026, with the U.S. Securities and Exchange Commission (the “SEC”), on March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company (“Parent”), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), Day One Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and Servier S.A.S., a French société par actions simplifiée, solely as a guarantor (“Guarantor” and together with Parent and Purchaser, the “Servier Parties”), entered into an Agreement and Plan of Merger (the “Merger Agreement”). All capitalized terms used but not otherwise defined herein have the meanings given to such terms in the Merger Agreement.

    Pursuant to the Merger Agreement, on March 26, 2026, Purchaser commenced a cash tender offer (the “Offer”) to purchase all of the issued and outstanding shares of common stock of the Company, par value $0.0001 per share (the “Shares”), at a price of $21.50 per share (the “Offer Price”), net to the seller in cash, without interest thereon, and less any applicable tax withholding, upon the terms and subject to the conditions set forth in the Offer to Purchase filed as Exhibit (a)(1)(A) to the Tender Offer Statement on Schedule TO filed by the Servier Parties with the SEC on March 26, 2026, as subsequently amended (the “Offer to Purchase”), and the related Letter of Transmittal.

    At one minute past 11:59 p.m., Eastern Time, on April 22, 2026 (the “Expiration Time”), the Offer expired and was not further extended. Computershare Trust Company, N.A., the depositary and paying agent for the Offer, advised Purchaser that, as of the Expiration Time, a total of 88,180,910 Shares were validly tendered and not properly withdrawn pursuant to the Offer, representing approximately 85.34% of the Shares issued and outstanding as of immediately following the consummation of the Offer. The number of Shares tendered satisfied the Minimum Tender Condition. As the Minimum Tender Condition and each of the other conditions of the Offer were satisfied, on April 23, 2026, Purchaser irrevocably accepted for payment all the Shares validly tendered and not properly withdrawn pursuant to the Offer prior to the Expiration Time, and will pay for such Shares as required by the Merger Agreement.

    Following the consummation of the Offer, on April 23, 2026, the Servier Parties completed the acquisition of the Company, pursuant to the terms and conditions of the Merger Agreement, through the merger of Purchaser with and into the Company, and without a meeting of stockholders of the Company in accordance with Section 251(h) of the General Corporation Law of the State of Delaware (the “DGCL”), with the Company continuing as the surviving corporation (the “Surviving Corporation”) and a wholly owned subsidiary of Parent (the “Merger”).

    At the effective time of the Merger (the “Effective Time”), each Share issued and outstanding immediately prior to the Effective Time (other than (i) Shares owned by the Company or any wholly owned subsidiary of the Company immediately prior to the Effective Time, (ii) Shares owned by Parent, Purchaser or any other subsidiary of Parent at the commencement of the Offer and owned by Parent, Purchaser or any other subsidiary of Parent immediately prior to the Effective Time, (iii) Shares irrevocably accepted for purchase by Purchaser in the Offer or (iv) Shares that are held by stockholders who are entitled to demand and properly demand appraisal for such Shares pursuant to and in compliance in all respects with Section 262 of the DGCL and do not fail to perfect or otherwise waive, withdraw or lose their right to appraisal with respect to such shares under the DGCL) was converted into the right to receive the Offer Price in cash, without interest thereon (the “Merger Consideration”), less any applicable tax withholding.

    Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase Shares granted under a Company Equity Incentive Plan or as a non-plan inducement award that was then-outstanding (collectively, the “Company Stock Options”) and unvested became fully vested. At the Effective Time, each Company Stock Option that was then outstanding was cancelled and the holder of such Company Stock Option became entitled to receive a cash payment without interest and less any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of Shares underlying such Company Stock Option and (ii) the excess of the Merger Consideration over the per Share exercise price of such Company Stock Option, if such Company Stock Option had a per Share exercise price less than the Merger Consideration. Any Company Stock Option that had an exercise price per Share that was equal to or greater than the Merger Consideration was cancelled for no consideration at the Effective Time.

    Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each restricted stock unit of the Company granted under a Company Equity Incentive Plan (collectively, the “Company RSUs”) that was then outstanding but unvested became immediately vested in full. At the Effective Time, each Company RSU that was


    then outstanding (including, without limitation, any restricted stock unit that had been deferred pursuant to the Company’s Director Equity Deferral Plan) was cancelled and the holder thereof became entitled to receive a cash payment, without interest thereon and less any applicable tax withholding, equal to the product obtained by multiplying (i) the Merger Consideration by (ii) the number of Shares underlying such Company RSU.

    The foregoing description of the Offer, the Merger and the Merger Agreement is not complete and is qualified in its entirety by reference to the Merger Agreement, a copy of which was filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K, filed with the SEC on March 6, 2026, and is incorporated herein by reference.

    Item 1.02 Termination of a Material Definitive Agreement.

    In connection with the closing of the transactions contemplated by the Merger Agreement, effective as of immediately prior to the Effective Time, the Company terminated the Company ESPP and, as of the Effective Time, each of the Company Stock Plans were terminated.

    In connection with the closing of the transactions contemplated by the Merger Agreement, on April 20, 2026, the Company provided written notice to Piper Sandler & Co. and JonesTrading Institutional Services LLC as sales agents (together, the “Agents”), of its election to terminate the Equity Distribution Agreement, dated June 1, 2022, between the Company and the Agents (the “Sales Agreement”). The termination is effective as of the Expiration Time. The material terms of the Sales Agreement are summarized in the Company’s Registration Statement on Form S-3 filed with the SEC on September 14, 2023.

    Item 2.01 Completion of Acquisition or Disposition of Assets.

    The disclosures under the Introductory Note of this Current Report on Form 8-K, Item 3.01, Item 5.01 and Item 5.03 are incorporated herein by reference.

    Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

    The disclosures under the Introductory Note of this Current Report on Form 8-K are incorporated herein by reference.

    On April 22, 2026, the Company (i) confirmed to the Nasdaq Stock Market LLC (“Nasdaq”) that the Offer was scheduled to expire at one minute past 11:59 p.m., Eastern Time, on April 22, 2026, (ii) notified Nasdaq of the anticipated consummation of the Merger prior to market open on April 23, 2026 and (iii) requested that Nasdaq halt trading of the Shares effective as of 8:00 p.m., Eastern Time, on April 22, 2026. On April 23, 2026, the Company confirmed to Nasdaq that the Merger had been consummated and requested that Nasdaq maintain the halt on trading of the Shares and file with the SEC a Form 25 Notification of Removal from Listing and/or Registration to delist and deregister the Shares under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Parent and the Surviving Corporation also intend to file with the SEC a Certification and Notice of Termination of Registration on Form 15 under the Exchange Act, requesting the termination of registration of the Shares under Section 12(g) of the Exchange Act and the suspension of the Company’s reporting obligations under Sections 13 and 15(d) of the Exchange Act.

    Item 3.03 Material Modification to Rights of Security Holders.

    The disclosures under the Introductory Note, Item 2.01, Item 3.01, Item 5.01 and Item 5.03 of this Current Report on Form 8-K are incorporated herein by reference.

    As a result of the Merger, at the Effective Time, each Share issued and outstanding immediately prior to the Effective Time (except as described in the Introductory Note of this Current Report on Form 8-K) was converted into the right to receive the Merger Consideration, without interest and less any applicable tax withholding. Accordingly, at the Effective Time, the holders of such Shares ceased to have any rights as stockholders of the Company, other than the right to receive the Merger Consideration.

     


    Item 5.01 Changes in Control of Registrant.

    The disclosures under the Introductory Note, Item 2.01, Item 3.01, Item 5.02 and Item 5.03 of this Current Report on Form 8-K are incorporated herein by reference.

    As a result of the consummation of the Offer and the Merger, there was a change in control of the Company, and Parent, as the direct parent company of Purchaser, acquired 100% of the voting securities of the Company. The aggregate consideration paid by Parent in connection with the Offer and the Merger is approximately $2.5 billion in equity value and is being funded by Servier and Parent with cash on hand and similar cash-like instruments.

    To the knowledge of the Company, there are no arrangements which may at a subsequent date result in a further change in control of the Company.

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    Pursuant to the Merger Agreement, as of the Effective Time, the directors of Purchaser immediately prior to the Effective Time became the directors of the Surviving Corporation. The directors of Purchaser immediately prior to the Effective Time were David K. Lee and Danielle Button. As of the Effective Time, Jeremy Bender, Habib Dable, Scott Garland, William Grossman, Natalie Holles, John Josey, Garry Nicholson and Saira Ramasastry each ceased to be directors of the Company and members of any committee of the Company’s board of directors. These departures were not a result of any disagreement between the Company and the directors on any matter relating to the Company’s operations, policies or practices.

    Pursuant to the Merger Agreement, as of the Effective Time, the officers of Purchaser immediately prior to the Effective Time became the officers of the Surviving Corporation. The officers of Purchaser immediately prior to the Effective Time were David K. Lee as President and Secretary, and Danielle Button as Treasurer. Effective immediately following the Effective Time, all of the incumbent officers of the Company, as of immediately prior to the Effective Time, were removed as officers of the Company.

    Biographical and other information regarding the new director and officers of the Surviving Corporation has been previously disclosed in Schedule I of the Offer to Purchase, which is incorporated herein by reference.

    Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

    Pursuant to the Merger Agreement, as of the Effective Time, the Company’s certificate of incorporation, as in effect immediately prior to the Effective Time, was amended and restated in its entirety (the “Amended and Restated Certificate of Incorporation”). In addition, pursuant to the Merger Agreement, as of the Effective Time, the bylaws of Purchaser, as in effect immediately prior to the Effective Time, became the bylaws of the Company (the “Amended and Restated Bylaws”).

    Copies of the Amended and Restated Certificate of Incorporation and the Amended and Restated Bylaws are filed as Exhibits 3.1 and 3.2, respectively, to this Current Report on Form 8-K, and are incorporated herein by reference.

     


    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit

    No.

       Description
    2.1*    Agreement and Plan of Merger, dated March 6, 2026, by and among the Company, Parent, Purchaser, and, solely for the purposes of Section 10.12, Guarantor (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by the Company with the SEC on March 6, 2026).
    3.1**    Amended and Restated Certificate of Incorporation of the Company, dated April 23, 2026.
    3.2**    Amended and Restated Bylaws of the Company, dated April 23, 2026.
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    *

    Schedules and similar attachments have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule will be furnished supplementally to the SEC upon request.

    **

    Filed herewith.

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

        DAY ONE BIOPHARMACEUTICALS, INC.
    Date: April 23, 2026     By:  

    /s/ David Lee

        David Lee
        President and Secretary
    Get the next $DAWN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DAWN

    DatePrice TargetRatingAnalyst
    3/10/2026$21.50Buy → Neutral
    H.C. Wainwright
    1/13/2026$34.00Buy
    TD Cowen
    8/19/2025$25.00Overweight
    Piper Sandler
    10/9/2024$32.00 → $33.00Buy
    Needham
    8/1/2024$11.00 → $24.00Underperform → Buy
    BofA Securities
    4/24/2024$30.00 → $33.00Buy
    Needham
    4/25/2023$34.00 → $9.00Buy → Underperform
    BofA Securities
    2/8/2023$40.00Overweight
    CapitalOne
    More analyst ratings

    $DAWN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Servier completes the acquisition of Day One Biopharmaceuticals

    Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the U.S. in pediatric low-grade glioma. Transaction also includes a strong oncology pipeline of clinical stage assets in rare cancers with high unmet needs. Transaction represents total equity value of approximately $2.5 billion.SURESNES, France, April 23, 2026 /CNW/ -- Servier, an independent international pharmaceutical group governed by a foundation, today announced the successful completion of the tender offer to acquire all of the issued and outstanding shares of common stock of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One"), a biopharmaceutical company dedicated to developing and com

    4/23/26 8:30:00 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care

    Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, March 19, 2026 /CNW/ -- USANewsGroup.com News Commentary -- The global oncology market is valued at $279.98 billion in 2026 and is on track to reach $748.17 billion by 2035[1], a structural realignment driven by the shift from single-agent treatments toward synergistic combination platforms and next-gen cell therapies. The immuno-oncology segment alone is projected to expand from $65.22 billion in 2025 to $170.19 billion by 2032[2], as a wave of combination therapy approvals converts tumors once resistant to immunotherapy into viable targets. Institutions are positioning for this shift through companies like Oncolytics Biotech (NASDAQ

    3/19/26 10:00:00 AM ET
    $DAWN
    $ENGN
    $GILD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio

    Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs. Transaction represents total equity value of approximately $2.5 billion.SURESNES, France and BRISBANE, Calif., March 6, 2026 /CNW/ -- Servier, an independent international pharmaceutical group governed by a foundation, and Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that they have entered into a definitive agreement for Servier to acquire Day One f

    3/6/26 10:21:00 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DAWN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Ai Day1 Llc bought $14,978,327 worth of shares (1,475,454 units at $10.15) (SEC Form 4)

    4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)

    10/20/23 4:02:31 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DAWN
    SEC Filings

    View All

    SEC Form 25-NSE filed by Day One Biopharmaceuticals Inc.

    25-NSE - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

    4/23/26 9:14:52 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Day One Biopharmaceuticals Inc.

    S-8 POS - Day One Biopharmaceuticals, Inc. (0001845337) (Filer)

    4/23/26 9:06:40 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Day One Biopharmaceuticals Inc.

    S-8 POS - Day One Biopharmaceuticals, Inc. (0001845337) (Filer)

    4/23/26 9:05:16 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DAWN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    April 30, 2024 - FDA Roundup: April 30, 2024

    For Immediate Release: April 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz

    4/30/24 3:20:20 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    April 26, 2024 - FDA Roundup: April 26, 2024

    For Immediate Release: April 26, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz

    4/26/24 3:10:22 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for OJEMDA issued to DAY ONE BIOPHARMACEUTICALS INC

    Submission status for DAY ONE BIOPHARMACEUTICALS INC's drug OJEMDA (ORIG-1) with active ingredient TOVORAFENIB has changed to 'Approval' on 04/23/2024. Application Category: NDA, Application Number: 218033, Application Classification: Type 1 - New Molecular Entity

    4/24/24 12:52:43 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DAWN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Day One Biopharmaceuticals downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Day One Biopharmaceuticals from Buy to Neutral and set a new price target of $21.50

    3/10/26 8:39:03 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen resumed coverage on Day One Biopharmaceuticals with a new price target

    TD Cowen resumed coverage of Day One Biopharmaceuticals with a rating of Buy and set a new price target of $34.00

    1/13/26 8:59:51 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Day One Biopharmaceuticals with a new price target

    Piper Sandler initiated coverage of Day One Biopharmaceuticals with a rating of Overweight and set a new price target of $25.00

    8/19/25 8:33:40 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DAWN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Bender Jeremy returned 1,799,031 shares to the company, closing all direct ownership in the company (SEC Form 4) (for withholding tax)

    4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)

    4/23/26 4:40:56 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Head of Research and Dev. Vasconcelles Michael returned 4,397 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding obligation)

    4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)

    4/23/26 4:39:50 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    COO and CFO York Charles N Ii returned 312,025 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)

    4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)

    4/23/26 4:39:05 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DAWN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Day One Biopharmaceuticals Inc.

    SC 13G/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

    11/14/24 4:30:11 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Day One Biopharmaceuticals Inc.

    SC 13G/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

    11/7/24 9:24:55 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Day One Biopharmaceuticals Inc.

    SC 13G - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

    11/7/24 9:12:22 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DAWN
    Financials

    Live finance-specific insights

    View All

    Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance

    OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded pipeline with January 2026 acquisition of Mersana Therapeutics; Emi-Le in Phase 1 trial for adenoid cystic carcinoma (ACC) Day One to host conference call and webcast today, February 24, 4:30 p.m. ET BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today reports its finan

    2/24/26 4:00:00 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026

    BRISBANE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, February 24, 2026 at 4:30 p.m. ET to report financial results and discuss corporate progress for the fourth quarter and full-year 2025. Live audio of the webcast will be accessible by visiting the Events section of Day One's Media & Investors page. An archived version of the webcast will be available for replay in the Events section for 30 days follo

    2/10/26 8:30:00 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases

    Acquisition expands Day One's portfolio with novel antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le) Emi-Le has demonstrated early anti-tumor activity in an ongoing Phase 1 study for adenoid cystic carcinoma type-1 (ACC-1), a cancer with high unmet need and a lack of therapeutic options Day One will apply existing scientific and commercial capabilities to this investigational innovative therapeutic with a clear potential registration path Company to host conference call and webcast today, November 13, 8:00 am Eastern Time BRISBANE, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company

    11/13/25 6:00:00 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DAWN
    Leadership Updates

    Live Leadership Updates

    View All

    Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development

    Dr. Michael Vasconcelles brings more than 25 years of extensive oncology research, development and health technology expertise and corporate executive leadership to Day One Dr. Vasconcelles to drive pipeline creation and execution BRISBANE, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Michael Vasconcelles, M.D., has joined the Company as Head of Research & Development (R&D). "We are thrilled to welcome Mike during this pivotal time at Day One. As an

    6/10/25 8:30:00 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development

    Dr. Blackman's departure planned for end of 2024 Company's search for a new Head of R&D is ongoing BRISBANE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Samuel Blackman, M.D., Ph.D, co-founder and Head of Research & Development (R&D) of the Company, will be retiring effective at the end of 2024. He will continue to serve as a strategic advisor and consultant while the Company seeks a new Head of R&D. "Sam's passion for pediatric oncology

    11/20/24 4:30:00 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Day One Announces Two New Appointments to Board of Directors

    BRISBANE, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the appointments of Habib Dable and Dr. William Grossman to its Board of Directors. "We are excited to welcome Habib and Bill to our Board during this pivotal phase of our growth," said Jeremy Bender, Ph.D., chief executive officer of Day One. "Their deep expertise and leadership in oncology will further strengthen our Board and will be a great asset as we prepare for the potential launch of ou

    1/17/24 8:00:00 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care